Dr. Chengzheng Wang 王承正
Chief Physician
Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Individualized treatment for breast cancer, early diagnosis, and oncoplastic breast-conserving surgery. Performs immediate or delayed breast reconstruction using autologous tissue, implants, or mesh. Also treats benign breast tumors with minimally invasive techniques.
Dr. Wang holds a medical doctorate from Zhengzhou University. The physician focuses on diagnosing and researching common breast diseases, with expertise in early breast cancer diagnosis and individualized treatment. Dr. Wang has published over 20 professional papers, including SCI-indexed articles, and led or participated in multiple provincial-level research projects.
Professional roles
- Member, Breast Cancer Professional Committee, Henan Anti-Cancer Association
- Vice Chair, Henan Life Care Association
- Vice Chair, Breast Professional Committee, Zhengzhou Anti-Cancer Association
- Member, Breast Plastic Surgery Professional Committee, Precision and Digital Medicine Branch, China Association of Plastics and Aesthetics
Name order: in Chinese the family name comes first (Wang Chengzheng). Papers usually list the name as Chengzheng Wang or Wang C.
Selected publications
24 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Nat Commun, 2023 (first author): Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial. PubMed 37863916
- Biochem Biophys Res Commun, 2019 (senior author): Retraction notice to "miR-613 inhibits proliferation and invasion of breast cancer cell via VEGFA" [Biochem. Biophys. Res. Commun. 478/1 (2016) 274-278]. PubMed 31239039
- Biochem Biophys Res Commun, 2016 (senior author): miR-613 inhibits proliferation and invasion of breast cancer cell via VEGFA. PubMed 27449609
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion